title: Vaccination strategies for future influenza pandemics: a severity-based cost effectiveness analysis.
abstract: BACKGROUND
  A critical issue in planning pandemic influenza mitigation strategies is the delay between the arrival of the pandemic in a community and the availability of an effective vaccine. The likely scenario, born out in the 2009 pandemic, is that a newly emerged influenza pandemic will have spread to most parts of the world before a vaccine matched to the pandemic strain is produced. For a severe pandemic, additional rapidly activated intervention measures will be required if high mortality rates are to be avoided.
  
  
  METHODS
  A simulation modelling study was conducted to examine the effectiveness and cost effectiveness of plausible combinations of social distancing, antiviral and vaccination interventions, assuming a delay of 6-months between arrival of an influenza pandemic and first availability of a vaccine. Three different pandemic scenarios were examined; mild, moderate and extreme, based on estimates of transmissibility and pathogenicity of the 2009, 1957 and 1918 influenza pandemics respectively. A range of different durations of social distancing were examined, and the sensitivity of the results to variation in the vaccination delay, ranging from 2 to 6 months, was analysed.
  
  
  RESULTS
  Vaccination-only strategies were not cost effective for any pandemic scenario, saving few lives and incurring substantial vaccination costs. Vaccination coupled with long duration social distancing, antiviral treatment and antiviral prophylaxis was cost effective for moderate pandemics and extreme pandemics, where it saved lives while simultaneously reducing the total pandemic cost. Combined social distancing and antiviral interventions without vaccination were significantly less effective, since without vaccination a resurgence in case numbers occurred as soon as social distancing interventions were relaxed. When social distancing interventions were continued until at least the start of the vaccination campaign, attack rates and total costs were significantly lower, and increased rates of vaccination further improved effectiveness and cost effectiveness.
  
  
  CONCLUSIONS
  The effectiveness and cost effectiveness consequences of the time-critical interplay of pandemic dynamics, vaccine availability and intervention timing has been quantified. For moderate and extreme pandemics, vaccination combined with rapidly activated antiviral and social distancing interventions of sufficient duration is cost effective from the perspective of life years saved.
authors: School of Computer Science and Software Engineering, University of Western Australia, Stirling Highway, Crawley, Western Australia 6009, Australia.
authors: Joel K
authors: JK
authors: Kelso
authors: Nilimesh
authors: N
authors: Halder
authors: George J
authors: GJ
authors: Milne
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D003140:Communicable Disease Control / Q000191:economics / Q000379:methods*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000191:economics / Q000600:supply & distribution*; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D058873:Pandemics / Q000517:prevention & control*; D013997:Time Factors; D055815:Young Adult
chemical_list: D007252:Influenza Vaccines
references: J R Soc Interface. 2010 Apr 6;7(45):573-86
references: 19755499
references: J Infect Dis. 1998 Jul;178(1):53-60
references: 9652423
references: Vaccine. 2006 Nov 10;24(44-46):6701-7
references: 16806596
references: PLoS One. 2008;3(12):e4005
references: 19104659
references: Emerg Infect Dis. 2005 Sep;11(9):1355-62
references: 16229762
references: PLoS One. 2012;7(1):e30018
references: 22253862
references: PLoS One. 2008 Mar 12;3(3):e1790
references: 18335060
references: Nature. 2004 Dec 16;432(7019):904-6
references: 15602562
references: PLoS One. 2008 Feb 27;3(2):e1665
references: 18301743
references: PLoS One. 2007 Nov 28;2(11):e1220
references: 18043733
references: Emerg Infect Dis. 2006 Nov;12(11):1671-81
references: 17283616
references: Vaccine. 2008 Jul 4;26(29-30):3742-9
references: 18524428
references: Proc Biol Sci. 2007 Feb 22;274(1609):599-604
references: 17476782
references: Emerg Infect Dis. 2010 Feb;16(2):224-30
references: 20113551
references: Epidemiol Infect. 2008 Feb;136(2):166-79
references: 17445311
references: Stat Med. 2004 Nov 30;23(22):3469-87
references: 15505892
references: Clin Infect Dis. 2010 Jan 15;50(2):165-74
references: 20021259
references: Lancet. 2006 Sep 16;368(9540):991-7
references: 16980114
references: Ann Intern Med. 2009 Dec 15;151(12):829-39
references: 20008759
references: BMC Public Health. 2011 Dec 14;11:932
references: 22168242
references: Lancet. 2007 Aug 18;370(9587):580-9
references: 17707753
references: Epidemiol Rev. 1996;18(1):64-76
references: 8877331
references: Am J Epidemiol. 2004 Apr 1;159(7):623-33
references: 15033640
references: Science. 2009 Jun 19;324(5934):1557-61
references: 19433588
references: PLoS One. 2011;6(7):e22308
references: 21829456
references: Nature. 2011 Dec 07;480(7376):S1
references: 22158293
references: PLoS Med. 2006 Sep;3(9):e361
references: 16881729
references: J Epidemiol Community Health. 2008 Jun;62(6):555-9
references: 18477756
references: PLoS Med. 2009 Dec;6(12):e1000207
references: 19997612
references: PLoS One. 2010 Jun 28;5(6):e11341
references: 20596536
references: PLoS One. 2008 Jul 02;3(7):e2606
references: 18596963
references: Nature. 2012 May 02;486(7403):420-8
references: 22722205
references: BMC Public Health. 2011 Feb 25;11 Suppl 1:S1
references: 21356128
references: Value Health. 2009 Mar-Apr;12(2):226-33
references: 18671770
references: Science. 2012 Jun 22;336(6088):1534-41
references: 22723413
references: Science. 2012 Jun 22;336(6088):1541-7
references: 22723414
references: Nature. 2006 Jul 27;442(7101):448-52
references: 16642006
references: BMJ. 2009 Nov 19;339:b4571
references: 19926697
references: Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5935-40
references: 16585506
references: Lancet Infect Dis. 2012 Sep;12(9):687-95
references: 22738893
references: Science. 2005 Aug 12;309(5737):1083-7
references: 16079251
references: Nature. 2008 Apr 10;452(7188):750-4
references: 18401408
references: N Engl J Med. 2009 Dec 17;361(25):2405-13
references: 19745216
references: Theor Biol Med Model. 2010 Jan 07;7:1
references: 20056004
references: BMC Infect Dis. 2010 Jul 27;10:221
references: 20659348
references: BMJ. 2004 Jul 24;329(7459):224-7
references: 15271836
references: J Law Med. 2015 Mar;22(3):506-11
references: 25980184
references: BMC Public Health. 2010 Mar 29;10:168
references: 20346187
references: PLoS One. 2011;6(7):e22087
references: 21760957